Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
- 14 January 2020
- journal article
- research article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2020 (1)
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To evaluate the efficacy and safety of single combined (long‐ or short‐acting beta₂ agonist plus an inhaled corticosteroid (ICS)) inhaler only used as needed in people with mild asthma.Keywords
This publication has 25 references indexed in Scilit:
- Controlled Trial of Budesonide–Formoterol as Needed for Mild AsthmaNew England Journal of Medicine, 2019
- Exacerbation risk and characterisation of the UK’s asthma population from infants to old ageThorax, 2017
- Medication adherence and the risk of severe asthma exacerbations: a systematic reviewEuropean Respiratory Journal, 2014
- Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and childrenCochrane Database of Systematic Reviews, 2013
- Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adultsCochrane Database of Systematic Reviews, 2013
- Inhaled CorticosteroidsPharmaceuticals, 2010
- Asthma mortality among Swedish children and young adults, a 10-year studyRespiratory Medicine, 2008
- Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendationsAllergy, 2007
- Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnairesImmunology and Allergy Clinics of North America, 2005
- Effect of β agonists on inflammatory cellsJournal of Allergy and Clinical Immunology, 1999